CASI Pharmaceuticals (CASI) Competitors $3.34 +0.22 (+7.05%) (As of 09:30 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CASI vs. NLTX, MGNX, INBX, BMEA, FULC, SOPH, OPT, VTYX, KYTX, and AMRNShould you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Neoleukin Therapeutics (NLTX), MacroGenics (MGNX), Inhibrx (INBX), Biomea Fusion (BMEA), Fulcrum Therapeutics (FULC), SOPHiA GENETICS (SOPH), Opthea (OPT), Ventyx Biosciences (VTYX), Kyverna Therapeutics (KYTX), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. CASI Pharmaceuticals vs. Neoleukin Therapeutics MacroGenics Inhibrx Biomea Fusion Fulcrum Therapeutics SOPHiA GENETICS Opthea Ventyx Biosciences Kyverna Therapeutics Amarin Neoleukin Therapeutics (NASDAQ:NLTX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do institutionals and insiders believe in NLTX or CASI? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is NLTX or CASI more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Neoleukin Therapeutics' return on equity of -37.22% beat CASI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% CASI Pharmaceuticals -143.18%-181.52%-45.72% Which has higher earnings & valuation, NLTX or CASI? CASI Pharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.46CASI Pharmaceuticals$22.06M2.19-$26.94M-$2.23-1.40 Which has more volatility & risk, NLTX or CASI? Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Do analysts rate NLTX or CASI? CASI Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 92.31%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to NLTX or CASI? In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. CASI Pharmaceuticals' average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral CASI Pharmaceuticals Very Positive Does the MarketBeat Community favor NLTX or CASI? CASI Pharmaceuticals received 150 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 50.25% of users gave CASI Pharmaceuticals an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% CASI PharmaceuticalsOutperform Votes20050.25% Underperform Votes19849.75% SummaryCASI Pharmaceuticals beats Neoleukin Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CASI vs. The Competition Export to ExcelMetricCASI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.24M$6.92B$5.31B$9.28BDividend YieldN/A3.01%5.15%3.95%P/E Ratio-1.4011.05137.1517.86Price / Sales2.19253.281,245.75143.52Price / CashN/A22.6936.4435.67Price / Book1.725.404.654.95Net Income-$26.94M$151.97M$119.56M$225.72M7 Day Performance-8.77%-0.29%0.42%0.89%1 Month Performance-44.19%-4.80%-1.23%4.16%1 Year Performance-56.79%23.35%32.51%28.53% CASI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CASICASI Pharmaceuticals4.3359 of 5 stars$3.34+7.1%$6.00+79.6%-56.8%$51.64M$22.06M-1.50180Gap DownNLTXNeoleukin TherapeuticsN/A$23.72+7.9%N/A+74.8%$222.92MN/A-7.6390High Trading VolumeMGNXMacroGenics3.8257 of 5 stars$3.53+0.9%$7.63+116.0%-59.7%$221.54M$58.75M0.00430Positive NewsINBXInhibrx1.7611 of 5 stars$15.15-3.5%N/A-39.2%$219.37M$1.63M0.00166Short Interest ↑BMEABiomea Fusion3.6609 of 5 stars$6.00-1.6%$39.36+556.1%-47.8%$217.44MN/A0.0050Analyst ForecastShort Interest ↑News CoverageFULCFulcrum Therapeutics2.3287 of 5 stars$4.03+1.0%$9.33+131.6%-3.8%$217.38M$2.81M0.00100SOPHSOPHiA GENETICS2.5797 of 5 stars$3.32-1.8%$6.50+95.8%-21.5%$217.06M$62.37M0.00520Short Interest ↓News CoverageOPTOpthea2.7477 of 5 stars$3.65-1.6%$12.00+228.8%+46.6%$213.16M$120,000.000.008Gap UpVTYXVentyx Biosciences3.2401 of 5 stars$2.99-4.2%$10.00+234.4%+20.8%$211.42MN/A-1.3873KYTXKyverna Therapeutics2.5549 of 5 stars$4.87+7.0%$25.71+428.0%N/A$210.24M$7.03M0.0096News CoverageAMRNAmarin0.1881 of 5 stars$0.51+5.3%N/A-43.8%$208.58M$306.91M0.00360Analyst UpgradeNews Coverage Related Companies and Tools Related Companies Neoleukin Therapeutics Competitors MacroGenics Competitors Inhibrx Competitors Biomea Fusion Competitors Fulcrum Therapeutics Competitors SOPHiA GENETICS Competitors Opthea Competitors Ventyx Biosciences Competitors Kyverna Therapeutics Competitors Amarin Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CASI) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVance Exposes Wall Street Plan to Crash Bonds, Target TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.